DocWire News Editors

DocwireNews

Conducting genetic tests for variants of drug metabolizing enzyme (DME) is a potential option for personalizing medication prescribing, optimizing patient outcomes, and reducing healthcare resource utilization and costs.Researchers assessed the clinical utility and value of this preemptive pharmacogenetic test. The results of the study were presented at the AMCP Annual Meeting during a poster session titled &ldquo;Optimizing the Value of Pharmacogenetic Risk Screening Among Patients with Polypharmacy: A Healthcare System Experience.&rdquo;This cross-sectional study included 559,445 patients of all age groups who visited the University of Utah Healthcare and were included in the electronic data warehouse medical/pharmacy claims. They included patients who were taking three prescription drugs (one metabolized by a polymorphic DME) from June 1, 2015, to December 31, 2016.In this cohort, 236,822 patients (42%) were on one of the targeted drugs for genetic testing; of these, 54,509 patients met the full eligibility criteria. The mean patient age was 48 (standard deviation, 19 years), 42% were male, and 84% were white.Approximately 40% of the study population were taking at least one prescription drug metabolized by a polymorphic DME.Among the top 10 drugs across all age groups with major DME susceptibility were pain medications (tramadol and codeine) and antidepressants (citalopram, escitalopram, amitriptyline, nortriptyline, and paroxetine).Younger patients (&le;29 years) were more likely to be prescribed oral contraceptives (25%), while older patients (50-64 years) were more likely to be prescribed hormone replacement therapy (12%).The frequency of clopidogrel use increased with age group (3% among &le;29 years vs 17% among &ge;65 years).The trend of the genetic risk increased with age in the following clinics:<ul>
<li>Cardiology</li>
<li>Endocrinology</li>
<li>Surgery</li>
<li>Emergency medicine</li>
</ul>&ldquo;This information is important in identifying the right cohort for a pragmatic clinical trial, so appropriate outcomes measures can be identified in a population to determine the value of incorporating pharmacogenetic risk scores in routine clinical practice,&rdquo; the researchers concluded.Biltaji E, Biskupiak J, Sherwin C, McMillin G, Brixner D. Optimizing the Value of Pharmacogenetic Risk Screening Among Patients with Polypharmacy: A Healthcare System Experience. Abstract U50. Presented at the AMCP Managed Care &amp; Specialty Pharmacy Annual Meeting, April 23-26; Boston, MA.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

The Value of Using Pharmacogenetic Risk Scores in Routine Practice

AMCP 2018

Conducting genetic tests for variants of drug metabolizing enzyme (DME) is a potential option for personalizing medication prescribing, optimizing patient outcomes, and ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe